Charles Schwab
ANTX icon

Charles Schwab’s AN2 Therapeutics ANTX Stock Holding History

Charles Schwab’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,898
Closed -$295K – 3615
2023
Q1 		$295K Buy
29,898
+5,000
+20% +$55.6K ﹤0.01% 3094
2022
Q4 		$237K Buy
24,898
+14,709
+144% +$197K ﹤0.01% 3154
2022
Q3 		$178K Hold
10,189
– – ﹤0.01% 3177
2022
Q2 		$79K Buy
+10,189
New +$135K ﹤0.01% 3308

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Charles Schwab's ANTX Position: Q2 2023 in Review

Charles Schwab sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 29,898 shares — an estimated $295K sold.

Charles Schwab first reported a position in ANTX in Q2 2022 and held it in 4 quarters. The position peaked at $295K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

  • Charles Schwab reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Charles Schwab sold 29,898 AN2 Therapeutics shares in Q2 2023, an estimated $295K.
  • Charles Schwab first reported a position in AN2 Therapeutics in Q2 2022 and held it in 4 quarters.
  • Charles Schwab's AN2 Therapeutics position peaked at $295K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.